Today we’re announcing positive Phase 2 #clinicaltrial data for a potential treatment to fight #Alzheimers disease. Learn more on Lilly.com. “We are extremely pleased about these positive findings for a potential therapy for people living with Alzheimer’s, the only leading cause of death without a treatment that slows disease progression,” said Mark Mintun, M.D., vice president of pain and neurodegeneration. “With more than 30 years of dedication to finding solutions for this devastating disease, we are proud of our progress moving the field forward and advancing the science. These positive results give us hope for patients and their families.”